Reuters logo
BRIEF-Prometic receives fast track status for idiopathic pulmonary fibrosis drug
2017年10月25日 / 上午11点11分 / 1 个月前

BRIEF-Prometic receives fast track status for idiopathic pulmonary fibrosis drug

Oct 25 (Reuters) - Prometic Life Sciences Inc-

* Prometic receives fast track designation for PBI-4050 in development for idiopathic pulmonary fibrosis (IPF)

* Prometic Life Sciences Inc - ‍fast track designation follows recent FDA approval of pivotal Phase 2/3 clinical trial in IPF​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below